Thalidomide and Deep Vein Thrombosis in Multiple Myeloma: Risk Factors and Effect on Survival

This publication has 16 references indexed in Scilit:

• Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy
  Blood, 2002
• Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
  Blood Coagulation & Fibrinolysis, 2002
• Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
  Blood, 2001
• Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
  New England Journal of Medicine, 1999
• Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data
  Medicine, 1999
• Laboratory Diagnosis of the Thrombophilic State in Cancer Patients
  Seminars in Thrombosis and Hemostasis, 1999
• The Risk of a Diagnosis of Cancer after Primary Deep Venous Thrombosis or Pulmonary Embolism
  New England Journal of Medicine, 1998
• Venous thromboembolism and cancer
  The Lancet, 1998
• Thalidomide is an inhibitor of angiogenesis.
  Proceedings of the National Academy of Sciences, 1994
• THALIDOMIDE AND CONGENITAL ABNORMALITIES
  The Lancet, 1961